Johnson & Johnson (JNJ)
After hours:
| Previous close | 177.33 |
| Open | 177.01 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 174.66 - 177.26 |
| 52-week range | 155.72 - 186.69 |
| Volume | |
| Avg. volume | 7,012,690 |
| Market cap | 460.384B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 24.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.52 (2.55%) |
| Ex-dividend date | 21 Nov 2022 |
| 1y target est | N/A |
- GlobeNewswire
Purpose Investments Files Preliminary Prospectus for the First Yield-Focused Single-Stock ETFs
TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) has filed and been receipted for a preliminary prospectus by the Canadian securities regulators in connection with the proposed launch of the first yield-focused single-stock ETFs (as outlined below) (collectively, the “ETFs” or “Purpose Yield Shares”). ETF NamesUnderlying Issuer Security Apple (AAPL) Yield SharesApple Inc.Common stockAmazon (AMZ) Yield SharesAmazon.com Inc.Common stockTesla (TSLA) Yield
- Business Wire
Johnson & Johnson to Acquire Abiomed
NEW BRUNSWICK, N.J. & DANVERS, Mass., November 01, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an
- Business Wire
Johnson & Johnson Reports Q3 2022 Results
NEW BRUNSWICK, N.J., October 18, 2022--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. "Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses," said Joaquin Duato, Chief Executive Officer. "Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain con
